MorphoSys in a nutshell

You are here

Our mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Innovative technologies and smart development strategies are central to our approach.

For patients

Antibodies are used as therapeutic agents for the treatment of severe diseases and MorphoSys contributes to the development of novel and differentiated approaches. The Company has both the technical and scientific skills that are needed for the generation of optimized antibodies as therapeutics. Together with its partners from the pharmaceutical industry, MorphoSys uses this expertise to develop the medicines of tomorrow. The Company’s development activities include, but are not limited to indications such as cancer, inflammations and autoimmune diseases.

Only the most promising of MorphoSys’s own and partnered drug development programs reach clinical trials, where they are thoroughly evaluated with regards to their quality, safety and efficacy. Amongst these programs are highly promising compounds in late clinical stages which, if successfull, could enter the market within the next few years.

MorphoSys’s Expanded Access Policy

MorphoSys is committed to developing exceptional new treatments for patients suffering from serious diseases. 
Under the 21st Century Cures Act, the manufacturer or distributor of one or more investigational drugs for the diagnosis, monitoring, or treatment of one or more serious diseases or conditions shall make available its policy on how it evaluates and responds to requests submitted under section 561(b) of the Federal Food, Drug, and Cosmetic Act for provision of such a drug. 

MorphoSys is not currently making its investigational drugs available on an expanded access basis.

  1. Contact Information
    In case you have any questions regarding MorphoSys’ clinical trials in general please go to
  2. Request Procedures 
    MorphoSys is not currently making its investigational drugs available on an expanded access basis.
  3. General Criteria
    MorphoSys is not currently making its investigational drugs available on an expanded access basis. In the event MorphoSys decides to consider expanded access use, MorphoSys will evaluate and respond to each expanded access request that it receives on a case-by-case basis.
  4. Hyperlink
    In the event that MorphoSys decides to make its products available on an expanded access basis, this policy will be updated with a hyperlink to the expanded access record on after such record becomes active.

As authorized by the 21st Century Cures Act, MorphoSys may revise this expanded access policy at any time.  Additionally, the posting of this policy by MorphoSys shall not serve as a guarantee of access to any specific investigational drug by any individual patient.


For partners

Together with its partners from the pharmaceutical industry, MorphoSys is working on novel therapeutic approaches for severe diseases. The success of its partnerships is reflected by the variety of antibodies in development. Formerly, the Company’s technologies were paramount in forming the basis for partnering agreements. Today, alliances take several different forms. In order to further strengthen its existing portfolio, MorphoSys is constantly evaluating promising antibodies and other biomolecules at late preclinical or early clinical stages for in-licensing or co-development. Agreements on synergistic technologies add to the sustainable development of MorphoSys’s business.

For investors

MorphoSys is well-known in the pharmaceutical industry for its outstanding antibody technologies, but for some time now, the Company’s comprehensive pipeline of partnered and proprietary drug programs has taken center stage. By maximizing the number of unique programs, MorphoSys increases its future upside and reduces the risk which always accompanies the development of new medicines. MorphoSys’s distinctive business model has put the Company in a very strong financial position. This strength provides the foundation for a substantially increased investment in proprietary product and technology development, which in turn drives growth and value generation.

Innovative technologies, such as the Company’s leading antibody libraries HuCAL and Ylanthia, as well as smart development strategies, are central to the Company’s approach to drug discovery and development. MorphoSys, together with its partners, has built a therapeutic pipeline of more than 100 fully human antibody drug candidates, including advanced compounds and MorphoSys aims to further expand its proprietary development portfolio.

We aim to create substantial value with our R&D investments in both the partnered business and our proprietary development activities.

Jens Holstein
Chief Financial Officer